Diabetes Mellitus, Type 2
Conditions
Keywords
diabetes mellitus, resistant starch, sago, Sarawak, glycemic control, lipid control
Brief summary
This will be a parallel, randomised, double-blind, controlled trial. Upon successful screening, subjects will be randomised to either intervention arm or control arm in a ratio of 1:1. The subjects will consume either a drink containing 25g of Sarawak sago starch (intervention) or 25g of corn starch (control) in approximately 200mL of water, two times a day, before lunch and dinner for 12 weeks, in addition to a standardised dietary counselling for diabetes given by the hospital dietitian at baseline. The study endpoints will be evaluated after 12 weeks of starch consumption.
Detailed description
SAGODM trial is a parallel, randomised, double-blind, controlled trial on the effect of consuming sago starch for 12 weeks on glycaemic and lipid control in patients with type 2 diabetes mellitus. Diabetic patients who had HbA1C between 6.5% and 8.5% and had no change in the antidiabetic treatment for the past two months (primary inclusion criteria) were invited to participate in the trial. They were randomised to either the intervention arm or control arm in a ratio of 1:1. The subjects will consume either a drink containing 25g of Sarawak sago starch (intervention) or 25g of corn starch (control) in approximately 200mL of water, two times a day, before lunch and dinner for 12 weeks. They will receive standardised dietary counselling for diabetes given by the hospital dietitian at baseline. They will also be asked to record their dietary intake for three consecutive days every month. Blood samples will be taken at baseline and the last visit (post-12 weeks). The study endpoints will be evaluated after 12 weeks of starch consumption.
Interventions
DIETARY_SUPPLEMENTSago starch drink
Sarawak sago starch drink will be provided by CRAUN throughout the study. The starch drink will be supplied in sealed aluminium sachets. Each sachet contains 25g of study starch with cocoa flavouring.
DIETARY_SUPPLEMENTCorn starch drink
Corn starch drink will be provided by CRAUN throughout the study. The starch drink will be supplied in sealed aluminium sachets. Each sachet contains 25g of study starch with cocoa flavouring.
Sponsors
CRAUN Research Sdn. Bhd.
Sarawak General Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Masking description
Intervention (Sago starch) and control (corn starch) will be packed in individual aluminium sachets and will not be distinguishable from each other. The included subjects and investigators will be blinded from the study arm assignment. Randomisation and dispensation of the study starch will be done by the unblinded pharmacists only, who will not be involved in the care of the patients and study endpoint assessments.
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
1. 18 - 70 years old 2. Individual diagnosed with type 2 diabetes for at least three months 3. Not on any antidiabetic medications or on lifestyle modification or taking a stable dose of oral hypoglycaemic agents, with no change of dose and regime for the past eight weeks 4. Has HbA1C values of 6.5 - 8.5% within 28 days before commencing the study 5. Able to complete the clinical study, and 6. Able to provide written informed consent
Exclusion criteria
1. History of allergy to sago starch or corn starch 2. History of allergy to any other ingredients in the study foods 3. Clinically significant, active and acute cardiovascular disease 4. Clinically significant, stage 4 - 5 (estimated glomerular filtration rate \<30mL/min/1.73m2), chronic kidney failure 5. Clinically significant chronic liver disease or infection 6. Any malignancies 7. Regular use of hormone medications, anti-inflammatory medication, steroids, or other medications that might interfere with outcome measure 8. On a prescribed therapeutic diet 9. Taking part in weight loss programme 10. Clinically significant abnormal laboratory investigations 11. Other medical conditions or reasons, in the opinion of the Investigator or Research Physician, that make one unsuitable to join the study 12. Concurrent participation in other clinical studies involving intervention or treatment towards obesity, diabetes or impaired glucose 13. Pregnant or lactating mothers
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change of HbA1C value | 12 weeks | The change of HbA1C value at 12 weeks of intervention from baseline |
| Change of fasting blood glucose (FBG) level | 12 weeks | The change of FBG level at 12 weeks of intervention from baseline |
| Change of homeostasis model assessment (HOMA) of insulin resistance (HOMA-IR) value | 12 weeks | The change of HOMA of insulin resistant value at 12 weeks of intervention from baseline |
| Change of triglycerides level | 12 weeks | The change of triglycerides level at 12 weeks of intervention from baseline |
| Change of total cholesterol level | 12 weeks | The change of total cholesterol level at 12 weeks of intervention from baseline |
| Change of low density lipoprotein cholesterol (LDL-C) level | 12 weeks | The change of LDL-C level at 12 weeks of intervention from baseline |
| Change of high density lipoprotein cholesterol (HDL-C) level | 12 weeks | The change of HDL-C level at 12 weeks of intervention from baseline |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change of blood pressure from baseline | 12 weeks | The change of systolic and diastolic blood pressure at 12 weeks of intervention from baseline |
| Change of inflammatory marker levels: high-sensitive c-reactive protein (hs-CRP) level | 12 weeks | The change of hs-CRP level at 12 weeks of intervention from baseline |
| Change of heart rate from baseline | 12 weeks | The change of heart rate at 12 weeks of intervention from baseline |
| Change of inflammatory marker levels: interleukin 6 (IL-6) level | 12 weeks | The change of IL-6 level at 12 weeks of intervention from baseline |
| Change of inflammatory marker levels: blood ferritin level | 12 weeks | The change of blood ferritin level at 12 weeks of intervention from baseline |
| Change of total daily calorie intake | 12 weeks | The change of total daily calorie intake at 12 weeks of intervention from baseline |
| Change of body weight/body mass index (BMI) | 12 weeks | The change of BMI at 12 weeks of intervention from baseline |
| Change of body fat and visceral fat percentages | 12 weeks | The change of body fat and visceral fat percentages at 12 weeks of intervention from baseline |
| Change of waist-hip ratio from baseline | 12 weeks | The change of waist-hip ratio at 12 weeks of intervention from baseline |
Countries
Malaysia
Outcome results
None listed